左炔诺孕酮缓释系统联合达菲林治疗子宫腺肌症的疗效及对血清CA125 CA199 HE4的影响  

Curative Efficacy of Levonorgestrel Sustained Release System Combined with Triptorelin in Treatment of Adenomyosis of the Uterus and its Effect on Serum CA125 CA199 and HE4

作　　者：冯华萍[1] 赵绍杰[1] 唐艳[1] FENG Huaping;ZHAO Shaojie;TANG Yan(Wuxi Maternal and Child Health Care Hospital,Jiangsu Wuxi 214000,China)

机构地区：[1]江苏省无锡市妇幼保健院妇科,江苏无锡214000

出　　处：《河北医学》2019年第1期1-5,共5页Hebei Medicine

基　　金：江苏省自然科学基金项目;(编号:2012071)

摘　　要：目的:探讨左炔诺孕酮缓释系统联合达菲林治疗子宫腺肌症的疗效及对血清糖类抗原125(CA125)、糖类抗原199(CA199)、人附睾蛋白4(HE4)的影响。方法:选择2015年4月到2017年4月我院接诊的子宫腺肌症患者88例作为研究对象,以简单随机分组法分为观察组(n=40)和对照组(n=48),对照组使用左炔诺孕酮缓释系统治疗,观察组采用左炔诺孕酮缓释系统联合达菲林治疗。比较两组治疗后治疗效果及血清CA125、CA199、HE4水平变化、子宫体积、痛经评分、月经量评分及不良反应发生情况。结果:治疗后,观察组脱环率、阴道不规则出血均低于对照组(P<0.05),痛经缓解及月经改善均高于对照组(P<0.05);两组患者治疗前血清CA125、CA199、HE4水平无明显差异;治疗后,两组患者血清CA125、CA199、HE4水平均明显下降,且观察组患者血清CA125、CA199、HE4水平明显低于对照组(P<0.05);两组患者治疗前子宫体积、痛经评分、月经量评分无明显差异;治疗后,两组患者子宫体积、痛经评分、月经量评分均明显下降,且观察组患者子宫体积、痛经评分、月经量评分明显低于对照组(P<0.05);观察组不良反应总发生率为10.00%,显著低于对照组的35.42%(P<0.05)。结论:在子宫腺肌症患者中使用左炔诺孕酮缓释系统联合达菲林效果显著,可有效改善患者血清CA125、CA199、HE4水平,值得推广与运用。Objective:To investigate the efficacy of levonorgestrel sustained-release system combined with triptorelin in the treatment of adenomyosis and its effects on serum carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and human epididymal protein 4(HE4).Methods:88 patients with adenomyosis in our hospital were selected as the study subjects from April 2015 to April 2017,the randomized table method was used to divide the treatment group into the observation group(n=40)and the control group(n=48).The control group was treated with levonorgestrel sustained release system,and the observation group was treated with levonorgestrel sustained release system combined with triptorelin.The therapeutic effect and serum CA125,CA199 and HE4 levels,uterine volume,dysmenorrhea score,menstrual volume score and adverse reactions were compared between the two groups after treatment.Results:After treatment,the rate of annulus removal and irregular vaginal bleeding in the observation group were lower than those in the control group(P<0.05),and the relief of dysmenorrhea and the improvement of menstruation were higher than those in the control group(P<0.05).There was no significant difference in serum CA125,CA199 and HE4 levels between the two groups before treatment.After treatment,serum CA125,CA199 and HE4 levels of both groups decreased significantly,and serum CA125,CA199 and HE4 levels of the observation group were significantly lower than those of the control group(P<0.05).There was no significant difference in uterine volume,dysmenorrhea score and menstrual volume score between the two groups before treatment.After treatment,the uterine volume,dysmenorrhea score and menses score of the two groups decreased significantly,and the uterine volume,dysmenorrhea score and menses score of the observation group were significantly lower than those of the control group(P<0.05).The total incidence of adverse reactions in the observation group was 10.00%,significantly lower than the control group's 35.42%(P<0.05).Conclusion:In patie

关 键 词：子宫腺肌症 左炔诺孕酮缓释系统 达菲林 糖类抗原125 糖类抗原199 人附睾蛋白4 

分 类 号：R711.71[医药卫生—妇产科学]